title: Temporal effects of low-dose ACE inhibition on endothelial function in Type 1 diabetic patients.
abstract: OBJECTIVE
  Increased asymmetrical dimethylarginine (ADMA) is known to disturb endothelial function. ACE inhibitors decrease plasma ADMA levels in diseases associated with endothelial dysfunction. The effects of ACE inhibition on endothelial function and plasma ADMA levels in Type 1 diabetic patients was evaluated in the study.
  
  
  METHODS
  Thirty Type 1 diabetic patients [29+/-6 yr; females (F)/males (M): 18/12] and 29 controls (30+/-6 yr; F/M: 16/13) were recruited. Flow-mediated dilatation (FMD), plasma ADMAand thiobarbituric acid reactive substances (TBARs) were determined at baseline, on day 15 and 90 of 0.5 mg qd trandolapril therapy.
  
  
  RESULTS
  Compared to controls, baseline FMD levels were lower (4.7+/-2.0% vs 11.2+/-3.9%) (p<0.001), plasma ADMA (271.1+/-48.1 nmol/l vs 237.5+/-25.1 nmol/l) (p<0.05) and TBARs levels [4517.1+/-2366.9 nmol/malondialdehyde (MDA) vs 1775.9+/-598.7 nmol/MDA] (p<0.001) were higher in diabetic patients. On day 90 of trandolapril treatment, FMD (8.6+/-4.1%) (p<0.01) increased, ADMA levels (229.6+/-42.9 nmol/l) (p<0.001) decreased and TBARs levels (1531.8+/-1036.0 nmol/MDA) (p<0.001) decreased significantly. FMD was negatively correlated with plasma ADMA (r=-0.228, p<0.01), and TBARs levels (r=-0.244, p=0.02), whereas ADMA and TBARs levels were correlated positively (r=0.399, p<0.0001).
  
  
  CONCLUSIONS
  In conclusion, endothelial dysfunction is associated with elevated plasma ADMA levels in Type 1 diabetic patients. Low-dose ACE inhibition improves endothelial dysfunction and reduces ADMA levels. The antioxidant action of ACE inhibitors may play role in this process.
authors.affiliation: Section of Endocrinology and Metabolism, Marmara University Medical School, Istanbul, Turkey. dilekdy2002@yahoo.co
authors.forename: D
authors.initials: D
authors.lastname: Yazici
authors.forename: D Gogas
authors.initials: DG
authors.lastname: Yavuz
authors.forename: S
authors.initials: S
authors.lastname: Unsalan
authors.forename: A
authors.initials: A
authors.lastname: Toprak
authors.forename: M
authors.initials: M
authors.lastname: Yüksel
authors.forename: O
authors.initials: O
authors.lastname: Deyneli
authors.forename: H
authors.initials: H
authors.lastname: Aydin
authors.forename: H
authors.initials: H
authors.lastname: Tezcan
authors.forename: S
authors.initials: S
authors.lastname: Rollas
authors.forename: S
authors.initials: S
authors.lastname: Akalin
mesh_terms: D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D001120:Arginine / Q000031:analogs & derivatives / Q000097:blood; D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology*; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology*; D005260:Female; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D007211:Indoles; D017392:Thiobarbituric Acid Reactive Substances; C052035:trandolapril; C018524:N,N-dimethylarginine; D001120:Arginine